Zavante Targets Resistant Urinary Infections With I.V. Version Of Existing Drug

If approved, Zolyd will be the first intravenous epoxide antibiotic approved in the US, with greater potency than the oral version used first-line. Ex-US, the I.V. formulation has demonstrated a stable resistance profile.

Privately held Zavante Therapeutics Inc. hopes an intravenous formulation of an epoxide antibiotic first approved 20 years ago might hold the answer to addressing multi-drug resistant complicated urinary tract infections (cUTI), and now has Phase III data demonstrating non-inferiority against a control regimen of existing antibiotic combination therapy.

The San Diego biotech reported on April 6 that the ZEUS trial of Zolyd (fosfomycin) showed non-inferiority against a control...

Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

More from Anti-infective

More from Therapeutic Category